NovoCodex Biopharmaceuticals Co., Ltd. announced that it has received $60,000,000 in a round of funding on July 6, 2022. The transaction included participation from Zhejiang Runtu Co., Ltd., existing investors SDIC Capital Co.,Ltd, and Eli Lilly Investment Consulting (Shanghai) Co., Ltd.